Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations

Clinical Pharmacokinetics
P ColinDouglas J Eleveld


Uncertainty exists regarding the optimal dosing regimen for vancomycin in different patient populations, leading to a plethora of subgroup-specific pharmacokinetic models and derived dosing regimens. We aimed to investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the expected vancomycin exposure throughout life and for specific patient subgroups. A pooled population-pharmacokinetic model was built in NONMEM based on data from 14 different studies in different patient populations. Steady-state exposure was simulated and compared across patient subgroups for two US Food and Drug Administration/European Medicines Agency-approved drug labels and optimised doses were derived. The final model uses postmenstrual age, weight and serum creatinine as covariates. A 35-year-old, 70-kg patient with a serum creatinine level of 0.83 mg dL-1 (73.4 µmol L-1) has a V1, V2, CL and Q2 of 42.9 L, 41.7 L, 4.10 L h-1 and 3.22 L h-1. Clearance matures with age, reaching 50% of the maximal value (5.31 L h-1 70 kg-1) at 46.4 weeks postmenstrual age then declines with age to...Continue Reading


Jul 1, 1986·Clinical Pharmacokinetics·G R MatzkeD R Guay
Jun 1, 1999·The Journal of Antimicrobial Chemotherapy·F ThalhammerH Burgmann
May 9, 2000·Clinical Pharmacology and Therapeutics·M de HoogJ N van den Anker
May 20, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Wolfgang JungeGerhard Klein
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Dolores Santos BuelgaMaría José García
Jul 28, 2006·British Journal of Clinical Pharmacology·Brian J AndersonNicholas H G Holford
Nov 16, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·John E MurphyCarol V Bateman
Jan 19, 2008·Clinical Chemistry·Ferruccio CeriottiUNKNOWN IFCC Committee on Reference Intervals and Decision Limits (C-RIDL)
Oct 11, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Malin M RhodinNick H G Holford
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Mar 21, 2009·The Journal of Antimicrobial Chemotherapy·A H ThomsonA M Lovering
Oct 31, 2009·Burns : Journal of the International Society for Burn Injuries·Michael DoltonAndrew J McLachlan
Jul 24, 2010·International Journal of Clinical Pharmacology and Therapeutics·J L SánchezJ M Cornejo-Bravo
Jul 27, 2010·British Journal of Clinical Pharmacology·Natalia RevillaMaría Del Mar Fernández de Gatta
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Mar 8, 2011·Archives of Disease in Childhood. Fetal and Neonatal Edition·C OudinN Simon
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Jason A RobertsJeffrey Lipman
Apr 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ravina KullarMichael J Rybak
Apr 28, 2011·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Anthony JarkowskiMeir Wetzler
Nov 23, 2011·Therapeutic Drug Monitoring·Åsa M JohanssonJoseph F Standing
Dec 14, 2011·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Aug 1, 2012·Therapeutic Drug Monitoring·Aize Franciscus van der MeerJohannes H Proost
Feb 20, 2013·Clinical Pharmacokinetics·Stefanie HennigAlison H Thomson
May 8, 2013·Journal of Pharmaceutical Sciences·Nick HolfordBrian Anderson
Mar 26, 2014·Antimicrobial Agents and Chemotherapy·Wei ZhaoEvelyne Jacqz-Aigrain
Apr 12, 2014·Anesthesia and Analgesia·Douglas J EleveldMichel M R F Struys
Apr 29, 2014·The Lancet Infectious Diseases·Jason A RobertsUNKNOWN International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the Europe
Nov 17, 2015·The Journal of Antimicrobial Chemotherapy·Susanna E Medellín-GaribayEmilia Barcia
May 25, 2016·Antimicrobial Agents and Chemotherapy·Stefano CristalliniFabio Silvio Taccone
Aug 12, 2016·Clinical Pharmacokinetics·Elisa A M CalvierCatherijne A J Knibbe
Sep 17, 2016·BioMed Research International·Janko SamardzicKarel Allegaert
Oct 22, 2016·British Journal of Clinical Pharmacology·Eva GermovsekJoseph F Standing
May 17, 2017·Anesthesiology·Douglas J EleveldMichel M R F Struys
Oct 31, 2017·Therapeutic Drug Monitoring·Tõnis TasaIrja Lutsar
Nov 1, 2017·Antimicrobial Agents and Chemotherapy·Evan J ZasowskiMichael J Rybak
Apr 18, 2018·British Journal of Anaesthesia·T G ShortT D Egan
Sep 4, 2018·British Journal of Clinical Pharmacology·Dagan O LonsdaleJoseph F Standing

❮ Previous
Next ❯


Jan 12, 2020·Clinical Chemistry and Laboratory Medicine : CCLM·Camille RiffIsabelle Benz-de Bretagne
May 10, 2020·CPT: Pharmacometrics & Systems Pharmacology·Pieter J ColinAlison H Thomson
May 21, 2020·British Journal of Clinical Pharmacology·Bradley D MenzStephanie E Reuter
Feb 6, 2020·Clinical Pharmacokinetics·Abdullah AljutayliFahima Nekka
Oct 18, 2020·Clinical Pharmacology and Therapeutics·Jasmine H HughesRon J Keizer
Dec 28, 2019·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazutaka OdaHideyuki Saito
Jan 5, 2021·Anesthesiology·Douglas J Eleveld, Michel M R F Struys
Jan 16, 2021·Clinical Pharmacokinetics·Zi-Ran LiZheng Jiao
Apr 10, 2021·Expert Review of Clinical Pharmacology·Xiaohui HuangAjing Xu
Apr 30, 2021·International Journal of Clinical Pharmacy·Tatjana Van Der HeggenPieter A J G De Cock
May 19, 2021·Clinical Pharmacokinetics·Erin ChungWinnie Seto
Jul 28, 2021·Expert Review of Clinical Pharmacology·Quyen TuJason A Roberts
May 4, 2021·Critical Care Medicine·Sujita W NarayanAsad E Patanwala
Sep 17, 2021·Critical Care Medicine·Alexander H FlanneryRyan P Mynatt

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.